Session » Pediatric Rheumatology – ePoster II: SLE, Juvenile Dermatomyositis, & Scleroderma

Date: Monday, November 11, 2019

Time: 9:00AM-11:00AM

Meeting: 2019 ACR/ARP Annual Meeting

9:00AM-11:00AM: Abstract Number: 1751

A Systematic Literature Review of Efficacy and Safety of Biologic Agents for the Treatment of Juvenile Dermatomyositis

9:00AM-11:00AM: Abstract Number: 1753

Are Patterns of Early Disease Severity Predictive of Grade 12 Academic Achievement in Patients with Childhood-onset Chronic Rheumatic Diseases?

9:00AM-11:00AM: Abstract Number: 1735

Clinical Variables Influencing Prednisone Dosing Towards the Development of Corticosteroid Treatment Algorithms in Pediatric Proliferative Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 1736

Cognitive Impairment in Childhood-Onset Systemic Lupus Erythematosus: Early Detection with MRI Spectroscopy and Its Association with MOG Antibodies

9:00AM-11:00AM: Abstract Number: 1754

Comorbidities and Treatments in United States Youth with Chronic Musculoskeletal Pain

9:00AM-11:00AM: Abstract Number: 1741

Depression and Anxiety Symptoms in Childhood-Onset Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1726

Disease Activity and Health Care Utilization Among Young Adults with Childhood-onset Lupus Transitioning to Adult Care: Follow-Up Data from the Pediatric Lupus Outcomes Study

9:00AM-11:00AM: Abstract Number: 1725

Disease Activity in Childhood-Onset Systemic Lupus Erythematosus: Initial Analysis of the Childhood Arthritis and Rheumatology Research Alliance Registry

9:00AM-11:00AM: Abstract Number: 1724

Disease Manifestations and Impact on Quality of Life in Subjects with Pre-Pubertal Onset Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1742

Ethnicity and Neonatal Lupus Erythematosus Manifestations Risk in a Large Multi-Ethnic Cohort

9:00AM-11:00AM: Abstract Number: 1732

Evaluating the New 2018 ACR/EULAR SLE Classification in Pediatric Patients

9:00AM-11:00AM: Abstract Number: 1745

Exercise Improves Arterial Inflammation in Childhood-onset Takayasu Arteritis: A Randomized Controlled Trial

9:00AM-11:00AM: Abstract Number: 1756

Health-related Social Media Use by Parents of Children with Rheumatic Diseases

9:00AM-11:00AM: Abstract Number: 1746

Identifying Additional Risk Factors for Arterial and Venous Thrombosis Among Pediatric Antiphospholipid Antibodies Carriers

9:00AM-11:00AM: Abstract Number: 1730

Impact of Preceding and Co-existing Autoimmune Cytopenias on Severity of Childhood-onset Systemic Lupus Erythematosus: A Single-Center Retrospective Cohort Study

9:00AM-11:00AM: Abstract Number: 1755

Improving Adolescent Health Care Transition: Piloting the Transition Readiness Assessment Questionnaire

9:00AM-11:00AM: Abstract Number: 1749

Improving Eye Screening Among Pediatric Rheumatology Patients Receiving Hydroxychloroquine: Experience of a Quaternary Care Center

9:00AM-11:00AM: Abstract Number: 1748

Incidence of Retinopathy in Individuals Who Initiated Hydroxychloroquine Therapy During Childhood

9:00AM-11:00AM: Abstract Number: 1729

Infections and Mortality in 230 Childhood Lupus Patients: A Single Center Experience from North India

9:00AM-11:00AM: Abstract Number: 1752

Is Early Standardized Rituximab Therapy Sufficient for Toddlers with NMDAR Encephalitis?

9:00AM-11:00AM: Abstract Number: 1739

Kawasaki Disease Shock Syndrome – More Common Than We Think: Our Experience at Chandigarh, North India

9:00AM-11:00AM: Abstract Number: 1743

Kawasaki Disease: Is Intravenous Immunoglobulin Alone Adequate for the Child with Kawasaki Disease and Coronary Artery Lesions? A Retrospective Study of 65 Children with Kawasaki Disease from a Single North Indian Centre

9:00AM-11:00AM: Abstract Number: 1733

Long-term Renal Survival of Pediatric Onset Lupus Patients in a Population-Based Cohort

9:00AM-11:00AM: Abstract Number: 1734

Low Bone Mineral Density Was Associated with Lupus Nephritis Irrespective of Duration on Steroid Treatment in a Large Observational Study of Juvenile Systemic Lupus Erythematosus Patients

9:00AM-11:00AM: Abstract Number: 1740

Orange Brown Chromonychia in Kawasaki Disease: A Clinical Sign That Merits Greater Attention

9:00AM-11:00AM: Abstract Number: 1750

Pediatric Sjögren Syndrome: A Single-Center Experience

9:00AM-11:00AM: Abstract Number: 1728

Persistent Disease Activity Is Associated with Avascular Necrosis Development in Juvenile Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1747

Practice Variations in Treatment of Pediatric Anti-neutrophil Cytoplasmic Antibody (ANCA)-associated Vasculitis (AAV) with Renal Disease

9:00AM-11:00AM: Abstract Number: 1744

Serum Sickness Following Rituximab Treatment of Childhood-Onset SLE: A Single Center Experience

9:00AM-11:00AM: Abstract Number: 1737

Systemic Vascular Involvement in Kawasaki Disease: A Single Center Cohort

9:00AM-11:00AM: Abstract Number: 1738

Tracking Whole-Brain Volumetric Trends in Childhood-onset Systemic Lupus Erythematosus Patients in the Clinical Setting by Magnetic Resonance Imaging

9:00AM-11:00AM: Abstract Number: 1731

Validation of the 2017 Weighted Criteria in Pediatric Systemic Lupus Erythematosus (SLE)

9:00AM-11:00AM: Abstract Number: 1727

Worsening Disease Activity and Inability to Taper Corticosteroids in an Ethnically Diverse Cohort of Pediatric-Onset Lupus Patients After Transition to Adult Care

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].